Acute bipolar depression

A review of the use of olanzapine/fluoxetine

William V Bobo, Richard A. Epstein, Richard C. Shelton

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Depression is the predominant mood state in patients with bipolar I or II disorder over the course of illness. In spite of this, relatively few pharmacological treatments have been shown to be effective for treating depressive episodes associated with bipolar disorder in adults. Combination therapy with olanzapine and fluoxetine (OFC) is approved in the US for the treatment of acute depressive episodes in adults with bipolar I disorder. The short-term efficacy and safety of OFC for the treatment of bipolar depression are supported by results of four randomized, acute-phase studies. OFC has been associated with significantly greater depressive symptom improvement than placebo, and with higher rates of treatment response and remission than placebo and olanzapine monotherapy. OFC has also been shown to improve depressive symptoms to a greater degree than modestly dosed lamotrigine, with similar rates of positive treatment response and remission. Although OFC was generally well tolerated in each of the reviewed studies, clinically significant weight gain, adverse changes in glycemic and lipid profile, and prolactin elevation may complicate both short- and long-term treatment. OFC was not associated with significantly increased risk of treatment-emergent mania in any of the reviewed studies. The broader effectiveness of OFC for the treatment of bipolar depression across clinically relevant subtypes (eg, patients with bipolar II disorder and comorbid substance abuse) and over long-term follow-up are needed. Comparative effectiveness studies of OFC and other available agents are also needed in order to determine its place among other available options for treating acute bipolar depressive episodes.

Original languageEnglish (US)
Pages (from-to)825-840
Number of pages16
JournalClinical Medicine Insights: Therapeutics
Volume2
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

olanzapine
Fluoxetine
Bipolar Disorder
Therapeutics
Depression
Placebos
Prolactin
Weight Gain
Substance-Related Disorders

Keywords

  • Bipolar depression
  • Bipolar disorder
  • Fuoxetine
  • Olanzapine
  • Olanzapine fuoxetine combination

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmaceutical Science
  • Pharmacology

Cite this

Acute bipolar depression : A review of the use of olanzapine/fluoxetine. / Bobo, William V; Epstein, Richard A.; Shelton, Richard C.

In: Clinical Medicine Insights: Therapeutics, Vol. 2, 2010, p. 825-840.

Research output: Contribution to journalArticle

@article{9f21f053668246c9bed9ca66ac562193,
title = "Acute bipolar depression: A review of the use of olanzapine/fluoxetine",
abstract = "Depression is the predominant mood state in patients with bipolar I or II disorder over the course of illness. In spite of this, relatively few pharmacological treatments have been shown to be effective for treating depressive episodes associated with bipolar disorder in adults. Combination therapy with olanzapine and fluoxetine (OFC) is approved in the US for the treatment of acute depressive episodes in adults with bipolar I disorder. The short-term efficacy and safety of OFC for the treatment of bipolar depression are supported by results of four randomized, acute-phase studies. OFC has been associated with significantly greater depressive symptom improvement than placebo, and with higher rates of treatment response and remission than placebo and olanzapine monotherapy. OFC has also been shown to improve depressive symptoms to a greater degree than modestly dosed lamotrigine, with similar rates of positive treatment response and remission. Although OFC was generally well tolerated in each of the reviewed studies, clinically significant weight gain, adverse changes in glycemic and lipid profile, and prolactin elevation may complicate both short- and long-term treatment. OFC was not associated with significantly increased risk of treatment-emergent mania in any of the reviewed studies. The broader effectiveness of OFC for the treatment of bipolar depression across clinically relevant subtypes (eg, patients with bipolar II disorder and comorbid substance abuse) and over long-term follow-up are needed. Comparative effectiveness studies of OFC and other available agents are also needed in order to determine its place among other available options for treating acute bipolar depressive episodes.",
keywords = "Bipolar depression, Bipolar disorder, Fuoxetine, Olanzapine, Olanzapine fuoxetine combination",
author = "Bobo, {William V} and Epstein, {Richard A.} and Shelton, {Richard C.}",
year = "2010",
doi = "10.4137/CMT.S1945",
language = "English (US)",
volume = "2",
pages = "825--840",
journal = "Clinical Medicine Insights: Therapeutics",
issn = "1179-559X",
publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - Acute bipolar depression

T2 - A review of the use of olanzapine/fluoxetine

AU - Bobo, William V

AU - Epstein, Richard A.

AU - Shelton, Richard C.

PY - 2010

Y1 - 2010

N2 - Depression is the predominant mood state in patients with bipolar I or II disorder over the course of illness. In spite of this, relatively few pharmacological treatments have been shown to be effective for treating depressive episodes associated with bipolar disorder in adults. Combination therapy with olanzapine and fluoxetine (OFC) is approved in the US for the treatment of acute depressive episodes in adults with bipolar I disorder. The short-term efficacy and safety of OFC for the treatment of bipolar depression are supported by results of four randomized, acute-phase studies. OFC has been associated with significantly greater depressive symptom improvement than placebo, and with higher rates of treatment response and remission than placebo and olanzapine monotherapy. OFC has also been shown to improve depressive symptoms to a greater degree than modestly dosed lamotrigine, with similar rates of positive treatment response and remission. Although OFC was generally well tolerated in each of the reviewed studies, clinically significant weight gain, adverse changes in glycemic and lipid profile, and prolactin elevation may complicate both short- and long-term treatment. OFC was not associated with significantly increased risk of treatment-emergent mania in any of the reviewed studies. The broader effectiveness of OFC for the treatment of bipolar depression across clinically relevant subtypes (eg, patients with bipolar II disorder and comorbid substance abuse) and over long-term follow-up are needed. Comparative effectiveness studies of OFC and other available agents are also needed in order to determine its place among other available options for treating acute bipolar depressive episodes.

AB - Depression is the predominant mood state in patients with bipolar I or II disorder over the course of illness. In spite of this, relatively few pharmacological treatments have been shown to be effective for treating depressive episodes associated with bipolar disorder in adults. Combination therapy with olanzapine and fluoxetine (OFC) is approved in the US for the treatment of acute depressive episodes in adults with bipolar I disorder. The short-term efficacy and safety of OFC for the treatment of bipolar depression are supported by results of four randomized, acute-phase studies. OFC has been associated with significantly greater depressive symptom improvement than placebo, and with higher rates of treatment response and remission than placebo and olanzapine monotherapy. OFC has also been shown to improve depressive symptoms to a greater degree than modestly dosed lamotrigine, with similar rates of positive treatment response and remission. Although OFC was generally well tolerated in each of the reviewed studies, clinically significant weight gain, adverse changes in glycemic and lipid profile, and prolactin elevation may complicate both short- and long-term treatment. OFC was not associated with significantly increased risk of treatment-emergent mania in any of the reviewed studies. The broader effectiveness of OFC for the treatment of bipolar depression across clinically relevant subtypes (eg, patients with bipolar II disorder and comorbid substance abuse) and over long-term follow-up are needed. Comparative effectiveness studies of OFC and other available agents are also needed in order to determine its place among other available options for treating acute bipolar depressive episodes.

KW - Bipolar depression

KW - Bipolar disorder

KW - Fuoxetine

KW - Olanzapine

KW - Olanzapine fuoxetine combination

UR - http://www.scopus.com/inward/record.url?scp=78650748167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650748167&partnerID=8YFLogxK

U2 - 10.4137/CMT.S1945

DO - 10.4137/CMT.S1945

M3 - Article

VL - 2

SP - 825

EP - 840

JO - Clinical Medicine Insights: Therapeutics

JF - Clinical Medicine Insights: Therapeutics

SN - 1179-559X

ER -